BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25589627)

  • 1. Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte-Derived HLA-Ligandome Using a Reverse Immunology Approach.
    Hombrink P; Hassan C; Kester MG; Jahn L; Pont MJ; de Ru AH; van Bergen CA; Griffioen M; Falkenburg JH; van Veelen PA; Heemskerk MH
    Clin Cancer Res; 2015 May; 21(9):2177-86. PubMed ID: 25589627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction.
    van der Zouwen B; Kruisselbrink AB; Frederik Falkenburg JH; Jedema I
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):760-9. PubMed ID: 24607556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach.
    Hombrink P; Hassan C; Kester MG; de Ru AH; van Bergen CA; Nijveen H; Drijfhout JW; Falkenburg JH; Heemskerk MH; van Veelen PA
    J Immunol; 2013 Apr; 190(8):3869-77. PubMed ID: 23475216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning.
    Van Bergen CA; Rutten CE; Van Der Meijden ED; Van Luxemburg-Heijs SA; Lurvink EG; Houwing-Duistermaat JJ; Kester MG; Mulder A; Willemze R; Falkenburg JH; Griffioen M
    Cancer Res; 2010 Nov; 70(22):9073-83. PubMed ID: 21062987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modification of Cytotoxic Lymphocytes with T Cell Receptor Specific for Minor Histocompatibility Antigen ACC-1Y].
    Pilunov AM; Kuchmiy AA; Sheetikov SA; Filkin SY; Romaniuk DS; Rosov FN; Efimov GA
    Mol Biol (Mosk); 2019; 53(3):456-466. PubMed ID: 31184611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of ITGB2.
    Pont MJ; van der Lee DI; van der Meijden ED; van Bergen CA; Kester MG; Honders MW; Vermaat M; Eefting M; Marijt EW; Kielbasa SM; Hoen PA; Falkenburg JH; Griffioen M
    Clin Cancer Res; 2016 Aug; 22(16):4185-96. PubMed ID: 26964570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Degree of predicted minor histocompatibility antigen mismatch correlates with poorer clinical outcomes in nonmyeloablative allogeneic hematopoietic cell transplantation.
    Larsen ME; Kornblit B; Larsen MV; Masmas TN; Nielsen M; Thiim M; Garred P; Stryhn A; Lund O; Buus S; Vindelov L
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1370-81. PubMed ID: 20353833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations.
    Hombrink P; Hadrup SR; Bakker A; Kester MG; Falkenburg JH; von dem Borne PA; Schumacher TN; Heemskerk MH
    PLoS One; 2011; 6(8):e22523. PubMed ID: 21850230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H60: A Unique Murine Hematopoietic Cell-Restricted Minor Histocompatibility Antigen for Graft-versus-Leukemia Effect.
    Choi EY; Choi K; Nam G; Kim W; Chung M
    Front Immunol; 2020; 11():1163. PubMed ID: 32587590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent detection of circulating minor histocompatibility antigen-specific CD8+ T cells in SCT recipients by combinatorial encoding MHC multimers.
    Broen K; Greupink-Draaisma A; Woestenenk R; Schaap N; Brickner AG; Dolstra H
    PLoS One; 2011; 6(6):e21266. PubMed ID: 21731686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4(+)and CD8(+)T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT.
    Steger B; Milosevic S; Doessinger G; Reuther S; Liepert A; Braeu M; Schick J; Vogt V; Schuster F; Kroell T; Busch DH; Borkhardt A; Kolb HJ; Tischer J; Buhmann R; Schmetzer H
    Immunobiology; 2014 Apr; 219(4):247-60. PubMed ID: 24315637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miHA-Match: computational detection of tissue-specific minor histocompatibility antigens.
    Feldhahn M; Dönnes P; Schubert B; Schilbach K; Rammensee HG; Kohlbacher O
    J Immunol Methods; 2012 Dec; 386(1-2):94-100. PubMed ID: 22985828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.
    Oosten LE; Blokland E; Kester MG; Falkenburg JH; van Halteren AG; Goulmy E
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):151-63. PubMed ID: 17241921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
    Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
    J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.
    Ofran Y; Kim HT; Brusic V; Blake L; Mandrell M; Wu CJ; Sarantopoulos S; Bellucci R; Keskin DB; Soiffer RJ; Antin JH; Ritz J
    Clin Cancer Res; 2010 Mar; 16(5):1642-51. PubMed ID: 20160060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized Whole Genome Association Scanning for Discovery of HLA Class I-Restricted Minor Histocompatibility Antigens.
    Fuchs KJ; Honders MW; van der Meijden ED; Adriaans AE; van der Lee DI; Pont MJ; Monajemi R; Kielbasa SM; 't Hoen PAC; van Bergen CAM; Falkenburg JHF; Griffioen M
    Front Immunol; 2020; 11():659. PubMed ID: 32362897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
    Zilberberg J; Feinman R; Korngold R
    Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Bykova NA; Malko DB; Efimov GA
    Front Immunol; 2018; 9():1819. PubMed ID: 30166983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minor histocompatibility antigens--targets of graft versus leukemia responses.
    Riddell SR; Murata M; Bryant S; Warren EH
    Int J Hematol; 2002 Aug; 76 Suppl 2():155-61. PubMed ID: 12430918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens.
    Fuchs KJ; van de Meent M; Honders MW; Khatri I; Kester MGD; Koster EAS; Koutsoumpli G; de Ru AH; van Bergen CAM; van Veelen PA; 't Hoen PAC; van Balen P; van den Akker EB; Veelken JH; Halkes CJM; Falkenburg JHF; Griffioen M
    Blood; 2024 May; 143(18):1856-1872. PubMed ID: 38427583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.